Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RedHill Biopharma ( (RDHL) ) has provided an announcement.
On October 16, 2025, RedHill Biopharma received a Nasdaq Staff Determination notification for not meeting the minimum stockholders’ equity requirements for continued listing. Following a transaction with Cumberland Pharmaceuticals, RedHill believes it now meets the equity requirement and plans to appeal the determination. The company remains listed on the Nasdaq Capital Market pending a hearing, but there is no guarantee of a favorable outcome or extension.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
RedHill Biopharma’s overall stock score is primarily impacted by its challenging financial performance, which is the most significant factor. Technical analysis suggests some potential for recovery in the medium term, but the lack of valuation metrics due to negative profitability further weighs down the score.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology in the U.S. market. The company promotes Talicia®, an FDA-approved drug for treating Helicobacter pylori infection, and is involved in various late-stage clinical development programs targeting conditions such as COVID-19, prostate cancer, and gastrointestinal diseases.
Average Trading Volume: 1,389,204
Technical Sentiment Signal: Sell
Current Market Cap: $5.76M
See more data about RDHL stock on TipRanks’ Stock Analysis page.